 |
 |
 |
 |
 |
 |
|
||||||||||||||
SELECT PUBLICATIONS
Jakesz R et al. Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). Proc ASCO 2005;Abstract 527.
Muss HB et al; Cancer and Leukemia Group B. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005;293(9):1073-81. Abstract
Oratz R et al. Impact of Oncotype DX™ on decision making in breast cancer clinical practice. San Antonio Breast Cancer Symposium 2005;Abstract 2049.
Paik S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24(23):3726-34. Abstract
Paik S et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26. Abstract
Perez EA et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. Proc ASCO 2007;Abstract 512.
Piccart-Gebhart MJ et al; HERA Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-72. Abstract
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract
Slamon D et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC
T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium 2006;Abstract 52.
Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 1.
Sparano JA. TAILORx: Trial assigning individualized options for treatment (Rx). Clin Breast Cancer 2006;7(4):347-50. No abstract available
| Table of Contents | Top of Page |
Editor:
Neil Love, MD
Interviews
Melvin J Silverstein, MD
- Select publications
David M Hyams, MD
- Select publications
Charles E Geyer Jr, MD
- Select publications
Hope S Rugo, MD
- Select publications
Highlights of a CME Symposium Held in Conjunction
with The American Society of Breast Surgeons Eighth
Annual Meeting
- Select publications
A CME Audio Series and Activity
 |
 |
 |
 |
 |
